Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...

Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk's patent on its branded drugs Ozempic and Wegovy is set to expire in January. "Canada is a major ...

Hims, a telehealth platform, joins a growing list of drugmakers that are looking to cash in on Novo Nordisk's lapsed patent on its GLP-1s. It's the first time the company will be operating in Canada.